A patient in Japan with HIV began antiretroviral therapy because of acute hepatitis B virus (HBV) 15 years ago, with low hepatitis B surface antibody, and experienced breakthrough HBV reactivation 4 months after switching from bictegravir/emtricitabine/tenofovir alafenamide to cabotegravir/rilpivirine. An immune escape mutation, E164V, was identified in the isolated HBV DNA.
All Keywords
【저자키워드】 viruses, HIV, HBV, Antiretroviral therapy, Japan, hepatitis B, Hepatitis B virus, Rilpivirine, cabotegravir, HBV reactivation, vaccine-escape mutation,
【저자키워드】 viruses, HIV, HBV, Antiretroviral therapy, Japan, hepatitis B, Hepatitis B virus, Rilpivirine, cabotegravir, HBV reactivation, vaccine-escape mutation,